Heliyon (May 2023)

Protease inhibitors from Theobroma cacao impair SARS-CoV-2 replication in vitro

  • Brenda Conceição Guimarães Santana,
  • Daisymara Priscila de Almeida Marques,
  • Andria dos Santos Freitas,
  • Monaliza Macêdo Ferreira,
  • Danielle de Sousa Lopes,
  • Flávia Fonseca Bagno,
  • Flávio Guimarães da Fonseca,
  • Jordana Grazziela Alves Coelho dos Reis,
  • Tiago Antônio de Oliveira Mendes,
  • Jane Lima dos Santos,
  • Carlos Priminho Pirovani

Journal volume & issue
Vol. 9, no. 5
p. e15860

Abstract

Read online

SARS-CoV-2 is a newly emerging virus from the Coronaviridae family that has already infected over 700 million people worldwide and killed over 6 million. This virus uses protease molecules to replicate and infect the host, which makes these molecules targets for therapeutic substances to eliminate the virus and treat infected people. Through the protein-protein molecular docking approach, we detected two cystatins from Theobroma cacao, TcCYS3 and TcCYS4, described as papain-like protease inhibitors. These inhibitors decreased SARS-CoV-2 genomic copies without toxicity to Vero cells. There is a need to perform comprehensive studies in relevant animal models and to investigate the action mechanisms of protease inhibitors from Theobroma cacao that control the replication of SARS-CoV-2 in human cells.

Keywords